Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Cited by (6,144)

Items 801–900 of 6,144

1. Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
   Mengda Xu, Kailun Zhang, Jiangping Song · 2021 · Frontiers in Pharmacology
2. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)
   Makhmudova, Umidakhon, Samadifar, Beasat, Maloku, Aurel, Haxhikadrija, Pellumb, Geiling, Jens-Arndt, Römer, Robert, Lauer, Bernward, Möbius-Winkler, Sven, Otto, Sylvia, Schulze, P. Christian et al. · 2023 · Clinical Research in Cardiology
3. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
   Stephen James Nicholls · 2023 · Kardiologia Polska
4. Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets
   Yuanliang Xia, Di Gao, Xu Wang, Bin Liu, Xue Shan, Yunpeng Sun, Dashi Ma · 2024 · Frontiers in Immunology
5. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
   Maya S. Safarova, Tia Bimal, Daniel E. Soffer, Benjamin J. Hirsh, Michael David Shapiro, Guy L. Mintz, Agnes Cha, Eugenia Gianos · 2024 · American Journal of Preventive Cardiology
6. Evolocumab and clinical outcomes in patients with cardiovascular disease
   Savvas Hadjiphilippou, Kausik Kumar Ray · 2017 · The Journal of the Royal College of Physicians of Edinburgh
7. Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction
   John N. Booth, Lisandro Damián Colantonio, Ligong Chen, Robert S. Rosenson, Keri L. Monda, Monika M. Safford, Meredith L. Kilgore, Todd M. Brown, Benjamin Taylor, Ricardo E. Dent et al. · 2017 · Circulation Cardiovascular Quality and Outcomes
8. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
   Yuichi Ikegami, Ikuo Inoue, Kaiji Inoue, Yuichi Shinoda, Shinichiro Iida, Seiichi Goto, Takanari Nakano, Akira Shimada, Mitsuhiko Noda · 2018 · npj Aging and Mechanisms of Disease
9. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
   Ilaria Dicembrini, Stefano Giannini, Benedetta Ragghianti, Edoardo Mannucci, Matteo Monami · 2019 · Journal of Endocrinological Investigation
10. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL
    Yuki Fujihara, Takamitsu Nakamura, Takeo Horikoshi, Jun–ei Obata, Daisuke Fujioka, Yosuke Watanabe, Kazuhiro Watanabe, Kiyotaka Kugiyama · 2019 · Circulation Journal
11. Dyslipidemia Profiles in Patients with Peripheral Artery Disease
    Aaron W. Aday, Brendan M. Everett · 2019 · Current Cardiology Reports
12. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
    Michael David Shapiro, David Joel Maron, Pamela Bowe Morris, Mikhail Kosiborod, Pratik B. Sandesara, Salim S. Virani, Amit Khera, Christie Mitchell Ballantyne, Seth J. Baum, Laurence S. Sperling et al. · 2019 · Journal of the American College of Cardiology
13. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
    Yanan Guo, Binjie Yan, Yu Gui, Zhi‐Han Tang, Shi Tai, Shenghua Zhou, Xi‐Long Zheng · 2020 · Journal of Cellular Physiology
14. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
    Kevin O’Fee, Elena Deych, Oriana Ciani, David Brown · 2021 · JAMA Internal Medicine
15. Lower extremity artery disease in patients with type 2 diabetes
    Buso, Giacomo, Aboyans, Victor, Mazzolai, Lucia · 2019 · European Journal of Preventive Cardiology
16. The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
    Scirica, Benjamin M., Lincoff, A. Michael, Lingvay, Ildiko, Bogdanski, Pawel, Buscemi, Silvio, Colhoun, Helen, Craciun, Anca-Elena, Ezhov, Marat, Hardt-Lindberg, Søren, Kleist Jeppesen, Ole et al. · 2024 · Journal of the American College of Cardiology
17. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
    Raul Dias Santos, Andrea Ruzza, G. Kees Hovingh, Claudia Stefanutti, François Mach, Olivier S Descamps, Jean Bergeron, Bei Wang, Andrea Bartuli, Paola Sabrina Buonuomo et al. · 2022 · The Lancet Diabetes & Endocrinology
18. Atherosclerotic Disease
    Amanda Maria Morrison, Alexander E. Sullivan, Aaron W. Aday · 2023 · Medical Clinics of North America
19. ROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis
    Ruiyi Yan, Xiao Zhang, Wenlong Xu, Jiayao Li, Yixin Sun, Shengyan Cui, Ran Xu, Wenjing Li, Liqun Jiao, Tao Wang · 2024 · Aging and Disease
20. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay
    Michael J. Wilkinson, Michael David Shapiro · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
21. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
    Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gabriella Kostelli, Sotirios Pililis, Loukia Pliouta et al. · 2025 · Journal of Clinical Medicine
22. Time to ditch HDL-C as a measure of HDL function?
    Graziella E. Ronsein, Jay W. Heinecke · 2017 · Current Opinion in Lipidology
23. Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
    Michael B. Boffa, Saverio Stranges, Neil S. Klar, Patrick M. Moriarty, Gerald Francis Watts, Marlys L. Koschinsky · 2018 · Journal of clinical lipidology
24. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy
    Vivianne Presta, Ilaria Figliuzzi, Francesca Miceli, Roberta Coluccia, Federica Fogacci, Arrigo F.G. Cicero, Andrea Ferrucci, Claudio Borghi, Massimo Volpe, Giuliano Tocci et al. · 2019 · Atherosclerosis
25. Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
    Benn, Marianne, Tybjærg-Hansen, Anne, Nordestgaard, Børge G. · 2019 · Journal of the American College of Cardiology
26. Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies
    Alireza Fatahian, Saeed Mohammadian Haftcheshmeh, Sara Azhdari, Helaleh Kaboli Farshchi, Banafsheh Nikfar, Amir Abbas Momtazi‐Borojeni · 2020 · Reviews of physiology, biochemistry and pharmacology
27. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience
    Roberto Scicali, Antonino Di Pino, Francesca Urbano, Viviana Ferrara, Simona Marchisello, Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Agata Maria Rabuazzo, Francesco Purrello et al. · 2020 · Nutrition Metabolism and Cardiovascular Diseases
28. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study
    Janik, Matthew J., Urbach, Dorothea V., van Nieuwenhuizen, Elane, Zhao, Jian, Yellin, Ori, Baccara-Dinet, Marie T., Pordy, Robert, Manvelian, Garen · 2021 · Atherosclerosis
29. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
    Albosta, Michael S, Grant, Jelani K, Taub, Pam, Blumenthal, Roger S, Martin, Seth S, Michos, Erin D · 2023 · Vascular Health and Risk Management
30. Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
    Talasaz, Azita H., Ho, Ai‐Chen (Jane), Bhatty, Fawzia, Koenig, Rachel A., Dixon, Dave L., Baker, William L., Van Tassell, Benjamin W. · 2021 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
31. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
    Michel Zeitouni, Pierre François Sabouret, Mathieu Kernéis, Johanne Silvain, Jean‐Philippe Collet, Éric Bruckert, Gilles Montalescot · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
32. Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis
    Haikun Liu, Geoffrey A. Pietersz, Karlheinz Peter, Xiaowei Wang · 2022 · Journal of Nanobiotechnology
33. Coronary artery calcium scores indicating secondary prevention level risk: Findings from the CAC consortium and FOURIER trial
    Omar Dildar a Dzaye, Alexander C. Razavi, Erin D. Michos, Martin Bødtker Mortensen, Zeina Dardari, Khurram Nasir, Albert Danso Osei, Allison W. Peng, Ron Blankstein, John H. Page et al. · 2022 · Atherosclerosis
34. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
    Zhen Feng, Xiaoye Li, Wai Kei Tong, Qingfeng He, Xiao Li Zhu, Xiaoqiang Xiang, Zhijia Tang · 2022 · Frontiers in Pharmacology
35. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
    L. Masana, Núria Plana, Natàlia Andreychuk, Daiana Ibarretxe · 2023 · Pharmacological Research
36. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
    Bosco, Giosiana, Di Giacomo Barbagallo, Francesco, Spampinato, Salvatore, Lanzafame, Lorena, Di Pino, Antonino, Piro, Salvatore, Purrello, Francesco, Scicali, Roberto · 2023 · Journal of Clinical Medicine
37. A robust cis-Mendelian randomization method with application to drug target discovery
    Zhaotong Lin, Wei Pan · 2024 · Nature Communications
38. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
    Michael David Shapiro, Joshua Miles, Hagai Tavori, Sergio Fazio · 2017 · Annals of Internal Medicine
39. The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development
    Joshua C. Denny, Sara L. Van Driest, Wei‐Qi Wei, Dan M. Roden · 2017 · Clinical Pharmacology & Therapeutics
40. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes
    Michel Paul Hermans, Paul Elie Valensi · 2018 · Current Opinion in Endocrinology Diabetes and Obesity
41. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
    Dhrubajyoti Bandyopadhyay, Arshna Qureshi, Sudeshna Ghosh, Kumar Ashish, Lyndsey R. Heise, Adrija Hajra, Raktim Kumar Ghosh · 2018 · Journal of Lipids
42. Evolocumab in Patients with Cardiovascular Disease
    Konstantinos C. Koskinas, Stephan Windecker · 2017 · New England Journal of Medicine
43. Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
    Hayato Tada, Atsushi Nohara, Masa‐aki Kawashiri · 2018 · Nutrients
44. Therapeutic Genome Editing in Cardiovascular Diseases
    David M. German, Shoukhrat M. Mitalipov, Anusha Mishra, Sanjiv Kaul · 2019 · JACC Basic to Translational Science
45. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis
    Conor S. Judge, Sarah Ruttledge, Maria M. Costello, Robert Murphy, Elaine A. Loughlin, Alberto Alvarez‐Iglesias, John P. Ferguson, Sarah Gorey, Aoife M. Nolan, Michelle D. Canavan et al. · 2019 · Journal of Stroke and Cerebrovascular Diseases
46. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand
    Yaling Han, Ji-yan Chen, Vijay Chopra, Shuyang Zhang, Guohai Su, Changsheng Ma, Zhouqing Huang, Yingyan Ma, Zhuhua Yao, Zuyi Yuan et al. · 2019 · Journal of clinical lipidology
47. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial
    Kazuma Oyama, Robert Patrick Giugliano, Minao Tang, Marc P. Bonaca, Jeffrey L. Saver, Sabina A. Murphy, Andrea Ruzza, ANTHONY C. KEECH, Peter S. Sever, Marc Steven Sabatine et al. · 2021 · European Heart Journal
48. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
    Matthew T. Roe, Qian H Li, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Patricio A López-Jaramillo, Renato D. Lópes et al. · 2019 · Circulation
49. Information and consensus document for the detection and management of chronic kidney disease
    Rafael García Maset, Jordi Bover, J. Segura, Marian Goicoechea Diezhandino, Jesús Cebollada del Hoyo, Javier Escalada, Lorenzo Fácila, Javier Gamarra, José Antonio García‐Donaire, Lisardo García Matarin et al. · 2022 · Nefrología (English Edition)
50. Clinical Updates in Coronary Artery Disease: A Comprehensive Review
    Andrea Bottardi, Guy F. A. Prado, Mattia Lunardi, Simone Fezzi, Gabriele Pesarini, Domenico Tavella, Roberto Scarsini, Flavio Luciano Ribichini · 2024 · Journal of Clinical Medicine
51. Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science: A Science Advisory From the American Heart Association
    Yuri Kim, Andrew Paul Landstrom, Svati Hasmukh Shah, Joseph C. Wu, Christine E. Seidman · 2024 · Circulation
52. Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
    J Berger, Angel Loza‐Valdes, Jesper Gromada, Norma N. Anderson, Jay D. Horton · 2017 · Journal of Lipid Research
53. New perspectives on CKD-induced dyslipidemia
    Marcelino Bermúdez-López, David Arroyo, Àngels Betriu, L. Masana, Elvira Fernández, José Manuel Valdivielso · 2017 · Expert Opinion on Therapeutic Targets
54. Biomarkers in stable coronary artery disease
    Cian P. McCarthy, John William McEvoy, James L. Januzzi · 2017 · American Heart Journal
55. Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study
    Joshua A. Bell, Mark Hamer, Rebecca Claire Richmond, Nicholas John Timpson, David Carslake, George Davey Smith · 2018 · PLoS Medicine
56. Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics
    Speranza Donatella Rubattu, Massimo Volpe · 2019 · International Journal of Molecular Sciences
57. Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine
    Angus A. W. Baumann, Aashka Mishra, Matthew Ian Worthley, Adam J. Nelson, Peter James Psaltis · 2020 · Therapeutic Advances in Chronic Disease
58. Nanoparticle-based “Two-pronged” approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux
    Hongliang He, Jing Wang, Paul J. Yannie, William J. Korzun, Hu Yang, Shobha Ghosh · 2020 · Biomaterials
59. Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement
    Luca Saba, Waleed Brinjikji, John David Spence, Max Wintermark, Maurício Castillo, Gert Jan de Borst, Qi Yang, Chun Yuan, Andrew J. Buckler, Myriam Edjlali et al. · 2021 · American Journal of Neuroradiology
60. Identification of a PCSK9-LDLR disruptor peptide with in vivo function
    Margaret E. Brousseau, Kevin B. Clairmont, Glen Spraggon, Alec N. Flyer, Andrei A. Golosov, Philipp Grosche, Jakal Amin, Jérôme André, Debra Burdick, Shari L. Caplan et al. · 2021 · Cell chemical biology
61. Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
    Jack Stewart, Katherine Addy, Sarah Campbell, Peter Wilkinson · 2020 · JRSM Cardiovascular Disease
62. PCSK9 in metabolism and diseases
    Ajoolabady, Amir, Pratico, Domenico, Mazidi, Mohsen, Davies, Ian G., Lip, Gregory Y.H., Seidah, Nabil, Libby, Peter, Kroemer, Guido, Ren, Jun · 2025 · Metabolism
63. Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update
    Rahul Jain, James A. Stone, Gina Agarwal, Jason G. Andrade, Simon Bacon, HARPREET SINGH BAJAJ, Brian Baker, Gemma Cheng, David A. Dannenbaum, Mark Gelfer et al. · 2022 · Canadian Medical Association Journal
64. Remnant cholesterol, low-density lipoprotein cholesterol, and incident cardiovascular disease among Koreans: a national population-based study
    Sang Jun Lee, Se-Eun Kim, Tae‐Hwa Go, Dae Ryong Kang, Ho-Seong Jeon, Young‐In Kim, Dong‐Hyuk Cho, Young Jun Park, Jung‐Hee Lee, Jun‐Won Lee et al. · 2023 · European Journal of Preventive Cardiology
65. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
    Gregory G. Schwartz, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Maja Bujas‐Bobanovic, Rafael Díaz, Sergio Fazio, Zlatko Fras, Shaun G. Goodman, Robert A. Harrington et al. · 2023 · European Heart Journal
66. Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
    Nicholas Marston, James P. Pirruccello, Giorgio E. M. Melloni, Frederick Kamanu, Marc P. Bonaca, Robert Patrick Giugliano, Benjamin M. Scirica, Stephen D. Wiviott, Deepak L. Bhatt, Philippe Gabríel Steg et al. · 2024 · Nature Medicine
67. Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial
    Philip D Adamson, Amanda L. Hunter, Michelle Claire Williams, Anoop S.V. Shah, David McAllister, Tania Pawade, Marc Richard Dweck, Nicholas L. Mills, Colin Berry, Nicholas A. Boon et al. · 2017 · Heart
68. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes
    Janne Pott, Valentin Schlegel, Andrej Teren, Katrin Horn, Holger Kirsten, Christina Blücher, Jüergen Kratzsch, Markus Loeffler, Joachim Thiery, Ralph Burkhardt et al. · 2018 · Circulation Genomic and Precision Medicine
69. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
    Massimo Raffaele Mannarino, Amirhossein Sahebkar, Vanessa Bianconi, Maria-Corina Șerban, Maciej Banach, Matteo Pirro · 2018 · Journal of clinical lipidology
70. Sterol Metabolism and Transport in Atherosclerosis and Cancer
    Yoshio Yamauchi, Maximillian A. Rogers · 2018 · Frontiers in Endocrinology
71. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach
    Renata Cífková, Jan V Pitha, Alena Krajčoviechová, Eva Králíková · 2019 · International Journal of Cardiology
72. Vaccination against atherosclerosis
    Kouji Kobiyama, Ryosuke Saigusa, Klaus F. Ley · 2019 · Current Opinion in Immunology
73. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options
    Adam N. Berman, Ron Blankstein · 2019 · Current Cardiology Reports
74. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two–Lipid Center Real-World Experience
    Giuseppe Mandraffino, Roberto Scicali, Javier Rodríguez‐Carrio, Francesca Savarino, Federica Mamone, Michele Scuruchi, Maria Cinquegrani, Egidio Imbalzano, Antonino Di Pino, Salvatore Piro et al. · 2020 · Journal of clinical lipidology
75. Clinical Pharmacology of Statins: an Update
    Nicola Ferri, Alberto Corsini · 2020 · Current Atherosclerosis Reports
76. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
    Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa M. Lalic, Dario Rahelić, Jan Škrha, Paul Elie Valensi, Antonio Ceriello · 2019 · Cardiovascular Diabetology
77. Low-Density Lipoprotein Cholesterol
    Christopher Paul Cannon · 2020 · Journal of the American College of Cardiology
78. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
    Kettunen, Johannes, Holmes, Michael V., Allara, Elias, Anufrieva, Olga, Ohukainen, Pauli, Oliver-Williams, Clare, Wang, Qin, Tillin, Therese, Hughes, Alun D., Kähönen, Mika et al. · 2019 · PLOS Biology
79. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
    Victoria W. Reynolds, Melissa E. Chinn, Jacob A. Jolly, Tara N. Kelley, Megan E. Peter, Leena Choi, Samuel Nwosu, Barbara Gisella Carranza Leon, Autumn D. Zuckerman · 2019 · Journal of clinical lipidology
80. Genome editing in large animal models
    Lucy H. Maynard, Olivier Humbert, Christopher W. Peterson, Hans‐Peter Kiem · 2021 · Molecular Therapy
81. Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
    Álvaro Petersen-Uribe, Marcel Kremser, Anne‐Katrin Rohlfing, Tatsiana Castor, Kyra Kolb, Valerie Dicenta, Fréderic Emschermann, Bo Li, Oliver Borst, Dominik Rath et al. · 2021 · International Journal of Molecular Sciences
82. Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans
    Xie, Baocai, Shi, Xiaochen, Li, Yan, Xia, Bo, Zhou, Jia, Du, Minjie, Xing, Xiangyang, Bai, Liang, Liu, Enqi, Alvarez, Fernando et al. · 2021 · PLOS Genetics
83. Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues
    Roshni Bhatnagar, Neal M. Dixit, Eric H. Yang, Tamer Sallam · 2022 · Frontiers in Cardiovascular Medicine
84. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
    Chen, Jingfei, Fang, Zhenfei, Luo, Qin, Wang, Xiao, Warda, Mohamad, Das, Avash, Oldoni, Federico, Luo, Fei · 2024 · Lipids in Health and Disease
85. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
    Michinari Nakamura · 2024 · Journal of Pharmacy & Pharmaceutical Sciences
86. Optimizing Management of Stable Angina
    Rocco Antonio Montone, Riccardo Rinaldi, Giampaolo Niccoli, Giuseppe Andò, Felice Gragnano, Raffaele Piccolo, Francesco Pelliccia, Elisabetta Moscarella, Marco Zimarino, Enrico Fabris et al. · 2024 · Journal of the American College of Cardiology
87. The Emerging Role of Inflammation in Cardiovascular Disease
    Brandon Keith Martinez, Charles Michael White · 2018 · Annals of Pharmacotherapy
88. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Wieneke Dijk, Cédric Le May, Bertrand Cariou · 2018 · Trends in Endocrinology and Metabolism
89. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
    L. M. Strilchuk, Federica Fogacci, Arrigo F.G. Cicero · 2019 · Expert Opinion on Drug Safety
90. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
    Maciej Banach, Éric Bruckert, Olivier S Descamps, Lars Ellegård, Ежов Марат Владиславович, Bernhard Föger, Zlatko Fras, Petri T. Kovanen, Gustavs Latkovskis, Winfried März et al. · 2019 · Atherosclerosis Supplements
91. Reduced plasma PCSK 9 response in patients with bacteraemia is associated with mortality
    Juha Rannikko, Dafne Jacome Sanz, Zsuzsanna Ortutay, Tapio Seiskari, Janne Aittoniemi, R. Huttunen, Jaana Syrjänen, Marko Pesu · 2019 · Journal of Internal Medicine
92. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future
    Neil J. Stone, Scott M. Grundy · 2019 · Progress in Cardiovascular Diseases
93. Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE)
    Guillaume Mahé, Gudrun Böge, Alessandra Bura-Rivière, Nabil Chakfé, J. Constans, Yann Gouëffic, Philippe Lacroix, Claire Le Hello, Gilles Pernod, Antonia Pérez‐Martin et al. · 2020 · Annals of Vascular Surgery
94. Calcific Aortic Stenosis—A Review on Acquired Mechanisms of the Disease and Treatments
    Banafsheh Zebhi, Mohamad Lazkani, David L. Bark · 2021 · Frontiers in Cardiovascular Medicine
95. mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor
    Sabrina E. Iskandar, Albert A. Bowers · 2022 · ACS Medicinal Chemistry Letters
96. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects
    Björnson, E., Packard, C.J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J. et al. · 2020 · Journal of Internal Medicine
97. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association
    Dinesh Kumar Kalra, Krishnaswami Vijayaraghavan, Geeta Sikand, Nihar R. Desai, Parag H. Joshi, Anurag Mehta, Wahida Karmally, Anish K. Vani, Shoeb J. Sitafalwalla, Raman Puri et al. · 2021 · Journal of clinical lipidology
98. An Oat β-Glucan Beverage Reduces LDL Cholesterol and Cardiovascular Disease Risk in Men and Women with Borderline High Cholesterol: A Double-Blind, Randomized, Controlled Clinical Trial
    Thomas M. S. Wolever, Maike Rahn, Elhadji M. Dioum, Susan E. Spruill, Adish Ezatagha, Janice E. Campbell, Alexandra L. Jenkins, YiFang Chu · 2021 · Journal of Nutrition
99. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
    Benjamin E. Peterson, Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle et al. · 2022 · Journal of the American Heart Association
100. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
     Toshiyuki Nishikido · 2023 · Cardiovascular Diabetology